Cargando…

Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate

BACKGROUND: In the initial absence of specific reversal agents for factor Xa inhibitors (FXa‐Is), prothrombin complex concentrate (PCC) as a hemostatic agent has been recommended by guidelines. Since 2017, idarucizumab has been registered for dabigatran reversal. Still, data on the clinical outcome...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bavalia, Roisin, Abdoellakhan, Rahat, Brinkman, Herm Jan M., Brekelmans, Marjolein P. A., Hamulyák, Eva N., Zuurveld, Marleen, Hutten, Barbara A., Westerweel, Peter E., Olie, Renske H., ten Cate, Hugo, Kruip, Marieke, Middeldorp, Saskia, Meijer, Karina, Coppens, Michiel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Article: Thrombosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292661/ https://www.ncbi.nlm.nih.gov/pubmed/32548555 http://dx.doi.org/10.1002/rth2.12336

Ejemplares similares

Clinical outcome of patients with a vitamin K antagonist‐associated bleeding treated with prothrombin complex concentrate
por: Brekelmans, Marjolein P. A., et al.
Publicado: (2017)

In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra
por: Brinkman, Herm Jan M., et al.
Publicado: (2022)

Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis
por: Brekelmans, Marjolein P. A., et al.
Publicado: (2017)

Risk of recurrence in women with venous thromboembolism related to estrogen‐containing contraceptives: Systematic review and meta‐analysis
por: Wiegers, Hanke M. G., et al.
Publicado: (2022)

Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in management of major bleeding
por: Abdoellakhan, Rahat A., et al.
Publicado: (2019)

Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study
por: Hamulyák, Eva N., et al.
Publicado: (2020)

Anti‐β2‐glycoprotein I and anti‐prothrombin antibodies cause lupus anticoagulant through different mechanisms of action
por: Noordermeer, Tessa, et al.
Publicado: (2021)

Reversing direct factor Xa or thrombin inhibitors: Factor V addition to prothrombin complex concentrate is beneficial in vitro
por: Brinkman, Herm Jan M., et al.
Publicado: (2022)

Paving the way for establishing a reference measurement system for standardization of plasma prothrombin time: Harmonizing the manual tilt tube method
por: van den Besselaar, Antonius M. H. P., et al.
Publicado: (2020)

Mapping the prothrombin-binding site of pseutarin C by site-directed PEGylation
por: Üstok, Fatma Işık, et al.
Publicado: (2022)

Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist-Related Intracranial Hemorrhage: A Retrospective Analysis
por: Abdoellakhan, Rahat Amadkhan, et al.
Publicado: (2016)

Postinterventional antithrombotic management after venous stenting of the iliofemoral tract in acute and chronic thrombosis: A systematic review
por: Notten, Pascale, et al.
Publicado: (2021)

Evaluation of the Prothrombin Fragment 1.2 in Patients with COVID-19
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials
por: Scheres, Luuk J. J., et al.
Publicado: (2018)

Sex‐specific differences in clot resolution 3 weeks after acute pulmonary embolism managed with anticoagulants—A substudy of the EINSTEIN‐PE study
por: Wiegers, Hanke M. G., et al.
Publicado: (2021)

Growth differentiation factor‐15 for prediction of bleeding in cancer patients
por: Mulder, Frits I., et al.
Publicado: (2021)

Donor tobacco smoking is associated with postoperative thrombosis after primary liver transplantation
por: Li, Yanni, et al.
Publicado: (2020)

Pulmonary embolism at autopsy in cancer patients
por: Gimbel, Inge A., et al.
Publicado: (2021)

Post‐thrombotic syndrome after upper extremity deep vein thrombosis: An international Delphi consensus study
por: de Kleijn, Robert J. C. M. F., et al.
Publicado: (2022)

Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism
por: Bistervels, Ingrid M., et al.
Publicado: (2022)

Nanobodies against factor XI apple 3 domain inhibit binding of factor IX and reveal a novel binding site for high molecular weight kininogen
por: Bar Barroeta, Awital, et al.
Publicado: (2022)

Does Fibrin Structure Contribute to the Increased Risk of Thrombosis in COVID-19 ICU Patients?
por: De Vries, Judith Juliana, et al.
Publicado: (2021)

Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban
por: Bosch, Floris T. M., et al.
Publicado: (2021)

Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation
por: Lu, Genmin, et al.
Publicado: (2020)

Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD‐AF registry
por: Seelig, Jaap, et al.
Publicado: (2020)

The bleeding phenotype in people with nonsevere hemophilia
por: Kloosterman, Fabienne R., et al.
Publicado: (2022)

Randomised controlled trial protocol to evaluate a fixed dose prothrombin complex concentrate against the variable dose in vitamin K antagonist related bleeding (PROPER3)
por: Abdoellakhan, Rahat A, et al.
Publicado: (2018)

Pregnancy in women with an inferior vena cava filter: a tertiary center experience and overview of the literature
por: Bistervels, Ingrid M., et al.
Publicado: (2021)

Development of a clinical prediction model for an international normalised ratio ≥ 4·5 in hospitalised patients using vitamin K antagonists
por: Dreijer, Albert R., et al.
Publicado: (2018)

A toolkit for the collection of thrombosis-related data elements in COVID-19 clinical studies
por: Siegal, Deborah M., et al.
Publicado: (2020)

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

SLC44A2 deficient mice have a reduced response in stenosis but not in hypercoagulability driven venous thrombosis
por: Tilburg, Julia, et al.
Publicado: (2020)

Potent and rapid reversal of the von Willebrand factor inhibitor aptamer BT200
por: Zhu, Shuhao, et al.
Publicado: (2020)

Risk scores for occult cancer in patients with unprovoked venous thromboembolism: Results from an individual patient data meta‐analysis
por: Mulder, Frits I., et al.
Publicado: (2020)

The development and characterization of a long acting anti‐thrombotic von Willebrand factor (VWF) aptamer
por: Zhu, Shuhao, et al.
Publicado: (2020)

Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D‐Dimer analysis: A prospective study
por: Posch, Florian, et al.
Publicado: (2020)

Safety of using the combination of the Wells rule and D‐dimer test for excluding acute recurrent ipsilateral deep vein thrombosis
por: van Dam, Lisette F., et al.
Publicado: (2020)

Model‐dependent contributions of FXII and FXI to venous thrombosis in mice
por: Grover, Steven P., et al.
Publicado: (2020)

Risk prediction of recurrent venous thrombosis; where are we now and what can we add?
por: Timp, Jasmijn F., et al.
Publicado: (2019)

Defective fibrin deposition and thrombus stability in Bambi (−/−) mice are mediated by elevated anticoagulant function
por: Crawley, James T. B., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_btdal64vuujei4eo05khgrj76r